Efficacy and Safety of Blue Light (453 nm) Treatment for Mild Psoriasis Vulgaris Over Three Months Compared to Vitamin D.

Psoriasis Vulgaris Clinical Trial

Official title:

Monocenter, Randomized, Blinded, Intraindividual Study Evaluating Efficacy and Safety of Blue Light (453 nm) Treatment for Mild Psoriasis Vulgaris Over Three Months Compared to Vitamin D

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02735187
• Other study ID #: Psoriasis-CT03
• Status: Completed
• Phase: N/A
• Start date: March 2016
• Est. completion date: August 2016

Study information

• Verified date: January 2019
• Source: Philips Light and Health
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Patients will be screened up to 28 days before start of treatment. During the screening visit, the purpose and procedures of the study will be explained to potential patients and informed consent will be obtained.

At the baseline visit, all inclusion and exclusion criteria will be re-assessed. Eligible patients will be randomized to treatment of the target area with either 30 minutes (group30) or 15 minutes (group15) blue light at 600 milliwatt per square centimeter (mW/cm²). Additionally, two study areas with similar clinical symptomatology will be determined and will be randomized to blue light treated area and Daivonex (Vitamin D) treated area.

After randomization, patients will be trained on a demonstrator device (no actual treatment to ensure investigator is blinded as to which group the patient is randomized to) as well as the Daivonex cream. After patients have been instructed, treatment of the areas will be applied daily (once per day, 5-7 times / week) at home for a treatment period of 12 weeks. During those 12 weeks, patients will return to the study site for safety and effectiveness assessments at week 2, 4, 8 and week 12. A phone call visit will be performed after one week of treatment to check for any adverse events or problems in handling the device or the cream. The visit at week 12 serves as end of treatment visit. The patients will be followed-up for another 4 weeks. Treatment responses will be photo documented.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 51
• Est. completion date: August 2016
• Est. primary completion date: August 2016
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 74 Years

Eligibility

Inclusion Criteria:

1. Signed and dated informed consent prior to any study-mandated procedure

2. Good health as determined by the Investigator

3. Willing and able to comply with study requirements

4. Skin type I-IV according to Fitzpatrick

5. Mild plaque-type psoriasis vulgaris with a Psoriasis Area and Severity Index (PASI) = 10 and body surface area (BSA) = 10 at screening.

6. Presence of two comparable psoriatic plaques suitable to be defined as study areas as follows:

• located on extremities (plaques located on the palms or sole of the feet are not suitable)

• Both areas located either on lower or upper extremity

• Can be located on the same extremity

• Distance between the two study areas = 11cm (border to border)

• If lesion is too large to be fully covered, partial treatment possible

7. Otherwise healthy according to physical examination

8. Aged 18 years up to =74 years

9. Reliable method of contraception for women of childbearing potential (i.e. low failure rate less than 1per cent per year; e.g. oral contraceptives, intra-uterine device (IUD) or transdermal contraceptive patch)

10. Willing to abstain from excessive sun / UV exposure (e.g. sunbath, solarium) during the course of the study

Exclusion Criteria:

General

1. Inmates of psychiatric wards, prisons, or other state institutions

2. Investigator or any other team member involved directly or indirectly in the conduct of the clinical study

3. Participation in another clinical trial within the last 30 days

4. Pregnant or lactating women Medical History

5. Photodermatosis and/or Photosensitivity

6. Porphyria and/or hypersensitivity to porphyrins

7. Patients with current diagnosis of erythrodermic, exfoliative or pustular psoriasis

8. Congenital or acquired immunodeficiency

9. Patients with any of the following conditions present on the study areas: naevi or signs of hyperpigmentation, viral (e.g. herpes or varicella) lesions of the skin, fungal and bacterial skin infections, parasitic infections and atrophic skin

10. Patients with any of the following conditions present or who have been diagnosed in the past with any of the following conditions on the study areas: skin cancer, severe actinic damage and other precancerous lesions

11. Patients with genetic deficiencies attached with increased sensitivity to light or increased risk to dermatologic cancer ( i.e. Xeroderma pigmentosum, Cockayne Syndrome, Bloom-Syndrome) Concomitant medication/treatment in medical history and during the study Required

• Treatment of target and control area with Excipial U10 Lipolotio (Galderma)

• Treatment of control area with Daivonex (Leo Pharma) Allowed

• Topical treatment of non-study areas with Vitamin D or WHO group I-II corticosteroids or mometasone Not allowed Within 3 months prior to baseline

• ustekinumab Within 2 months prior to baseline

• adalimumab, alefacept, infliximab Within 1 month prior to baseline

• Etanercept

• Systemic corticosteroids

• Retinoids

• Immunosuppressants (e.g. methotrexate, ciclosporin, azathioprine, chemotherapeutics)

• oral psoralen with ultraviolet A (PUVA)

• Topical or intranasal/inhalation therapy with potent or very potent (WHO group III-IV) corticosteroids

Within 2 weeks prior to baseline

• ultraviolet B light (UVB) / ultraviolet A light (UVA)

• Topical therapy with

• WHO group I-II corticosteroids

• Topical retinoids

• Vitamin D analogues

• Topical immunomodulators (e.g. calcineurin inhibitors)

• Anthracen derivatives

• Tar

• Salicylic acid

• Intranasal/inhalation therapy with WHO group I-II corticosteroids At baseline

• Photo-sensitizing medication (e.g. psoralen, tetracycline, nalidixic acid, furosemide, amiodarone, phenotiacine, chinclone, fibrates, hypericumperforatum, arnica, valerian, tar, psoralen, ketoprofen) or colours (e.g. thiazide, toluidine blue, eosin, methylene blue, rose Bengal, acridine)

• Initiation of, or expected changes in concomitant medication that may affect psoriasis vulgaris (e.g., beta blockers, anti-malaria drugs, lithium and angiotensin converting enzyme (ACE) inhibitors)

Related Conditions & MeSH terms

• Psoriasis
• Psoriasis Vulgaris

Intervention

Device:
• Blue light treatment
Phototherapy of localized psoriasis vulgaris plaque with a wearable device emitting blue light at 453nm.

Drug:
• Vitamin D
Treatment of contralateral localized psoriasis vulgaris plaque with Vitamin D creme (Daivonex)

Locations

Country	Name	City	State
Germany	Department of Dermatology and Allergology, Medical faculty of the RWTH Aachen	Aachen

Sponsors (1)

Lead Sponsor	Collaborator
Philips Light and Health

Country where clinical trial is conducted

Germany, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Hyperpigmentation of Treated Skin Areas Exposed to Blue Light and Control Area Exposed to Daivonex- Evaluation by Mexameter	Lesional tanning was measured objectively with a measurement device (Mexameter). The Mexameter delivers a two digit number for the brownish color of the skin (range 0-99). 0 = no tanning and 99 = maximal tanning.	week 2-16
Other	Adverse Events (Serious and Non-serious)	Adverse Events (serious and non-serious) collected during the study conduct.	week 0-16
Other	Adverse Device Effects	Adverse device effects collected during the study conduct.	week 0-16
Other	Device Deficiencies	The number of device deficiencies was collected throughout the study	week 0-12
Other	Thermal Comfort	Thermal comfort will be measured by questionaire: How comfortable was this temperature on your skin?	week 12
Primary	Change From Baseline (Visit 2) of the Local PSI of the Blue Light Treated Area (Group 30) as Compared to the VitaminD Treated Area (Control) at End of Treatment (Week 12).	The local Psoriasis severity index (LPSI) was adapted from the well known PASI. The investigator evaluated and graded the severity of erythema, induration, and scaliness as the key symptoms of psoriasis on the study areas (0-4). A total severity score was calculated as the sum of the three symptom ratings (range 0-12). The measure reported is the change in LPSI at end of treatment versus baseline. A negative change indicates an improvement of the LPSI.	week 12
Secondary	Change From Baseline (Visit 2) of the Local PSI of the Blue Light Treated Area (Group 15) as Compared to the VitaminD Treated (Control) Area at End of Treatment (Week 12).	The local Psoriasis severity index (LPSI) was adapted from the well known PASI. The investigator evaluated and graded the severity of erythema, induration, and scaliness as the key symptoms of psoriasis on the study areas (0-4 each). A total severity score was calculated as the sum of the three symptom ratings (range 0-12). The measure reported is the change in LPSI at end of treatment versus baseline. A negative change indicates an improvement of the LPSI.	week 12
Secondary	Change From Baseline in Patient Self-assessment of Severity of Psoriasis of the Blue Light Treated Area (Group 30) Compared to the VitaminD Treated (Control) Area at Week 12 (VAS Scale).	Patient Rating of severity of Psoriasis Plaques on a 0-10 cm Visual Analogue Scale (VAS) scale. VAS = 0 cm corresponds to no pain,, VAS = 10 cm corresponds to maximal imaginable pain.	week 12
Secondary	Change From Baseline in Patient Self-assessment of Severity of Psoriasis of the Blue Light Treated Area (Group 15) Compared to the VitaminD Treated (Control) Area at Week 12 (VAS Scale).	Patient Rating of severity of Psoriasis Plaques on 0-10 cm Visual Analogue Scale (VAS) scale. VAS = 0 corresponds to no symptoms of Psoriasis, VAS = 10 corresponds to most severe symptoms of Psoriasis.	week 12
Secondary	Lesional Erythema Measured by Mexameter Measured at End of Treatment.	Lesional erythema was measured objectively with a measurement device (Mexameter). The Mexameter delivers a two digit number for the redness of the skin (range 0-99). 0 = no redness and 99 = maximal redness.	week 12
Secondary	Patient Satisfaction (Week 12)	Patient satisfaction will be measured by questionnaire using the System usability score (SUS). The participant's scores for each question are converted to a new number, added together and then multiplied by 2.5 to convert the original scores of 0-40 to 0-100. Though the scores are 0-100, these are not percentages and should be considered only in terms of their percentile ranking. The higher the score the better the patient satisfaction the better the outcome. The lower the score the worse the patient satisfaction the worse the outcome.	week 12